{
    "id": 1672,
    "fullName": "EZH2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "EZH2 over exp indicates an over expression of the EZH2 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2146,
        "geneSymbol": "EZH2",
        "terms": [
            "EZH2",
            "ENX-1",
            "ENX1",
            "EZH2b",
            "KMT6",
            "KMT6A",
            "WVS",
            "WVS2"
        ]
    },
    "variant": "over exp",
    "createDate": "09/11/2014",
    "updateDate": "09/17/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1238,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, ER-positive breast cancer patients with increased EZH2 expression showed decreased progression-free survival after treatment with Nolvadex (tamoxifen) compared to patients with lower EZH2 expression levels (PMID: 25193989).",
            "molecularProfile": {
                "id": 2349,
                "profileName": "ESR1 pos EZH2 over exp"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 701,
                    "pubMedId": 25193989,
                    "title": "High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193989"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12773,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MC3629 decreased proliferation and induced apoptosis in human and mouse primary SHH-subgroup medulloblastoma (SHH-MB) derived stem-cell like cells expressing high EZH2 levels in culture, decreased viability of a human SHH-MB cell line expressing high EZH2 in culture, and increased apoptosis and decreased growth of human SHH-MB cell line derived stem-cell like cells in culture and in xenograft models (PMID: 28978137).",
            "molecularProfile": {
                "id": 24368,
                "profileName": "EZH2 over exp"
            },
            "therapy": {
                "id": 6645,
                "therapyName": "MC3629",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10708,
                    "pubMedId": 28978137,
                    "title": "The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978137"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7042,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQEZ5 inhibited proliferation of human EZH2-overexpressing non-small cell lung cancer cells in culture and induced tumor regression in mouse models of EZH2-overexpressing lung adenocarcinoma (PMID: 27312177).",
            "molecularProfile": {
                "id": 24368,
                "profileName": "EZH2 over exp"
            },
            "therapy": {
                "id": 4354,
                "therapyName": "JQEZ5",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6049,
                    "pubMedId": 27312177,
                    "title": "Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27312177"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2349,
            "profileName": "ESR1 pos EZH2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24368,
            "profileName": "EZH2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}